The moderate to severe chronic nociceptive pain market has boomed in the years since the removal of generic extended-release oxycodone from the US, growing in value to eclipse $10 billion. However, this reprieve will be short-lived with the pipeline and recently-launched drugs unable to fill the void left by generic erosion of OxyContin (controlled-release oxycodone, Purdue).
Reasons to Purchase
*Quantify the current and future size of the moderate to severe chronic nociceptive pain market
*Understand the country-specific impact of key events in the moderate to severe chronic nociceptive pain market during the forecast period 2010-19
*Identify potential licensing opportunities based on product portfolios and anticipated market needs
#N/A
Other selected research from the 'Pain' category:
Event Analysis and Response Service: Cox-2s - Cox-2 Crisis Dents Big Pharma Confidence
On 30th September 2004, Merck withdrew its blockbuster drug Vioxx from the global market after trial data reinforced the suspicion that it increased the risk of cardiovascular events. Vioxx was a widely used Cox-2 selective non-steroidal anti-inflammatory drug. Its withdrawal has sparked much speculation, regulatory review and a shakedown within the pharmaceutical industry. Learn More
Stakeholder Insight: HIV Related Neuropathic Pain - Useful Niche for Peripheral Companies
Fueled by the growing interest in neuropathic pain but keen to avoid competition with larger players, small companies recognize the commercial opportunity of the HIV-related neuropathic pain (HIVNP) market. Not only does HIVNP offer a well-served patient base and good awareness, it is also a useful stepping-stone to larger more prevalent neuropathic pain types and thus greater commercial gains. Learn More